Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of chidamide + tislelizumab + chemotherapy in advanced urothelial carcinoma
ChiCTR2000041541Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and tislelizumab in transitional cell carcinoma (TCC), sponsored by Chinese PLA General Hospital. Primary endpoint: objective response rate. Started Jan 2021; status: recruiting.
02
Drugs
tucidinostattislelizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2000041541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041541.